Jeil Pharm (002620) - Total Liabilities

Latest as of March 2026: ₩403.14 Billion KRW ≈ $273.20 Million USD

Based on the latest financial reports, Jeil Pharm (002620) has total liabilities worth ₩403.14 Billion KRW (≈ $273.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jeil Pharm (002620) long-term investment share to see how much of total assets are deployed in long-term investments.

Jeil Pharm - Total Liabilities Trend (2011–2025)

This chart illustrates how Jeil Pharm's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Jeil Pharm asset portfolio.

Jeil Pharm Competitors by Total Liabilities

The table below lists competitors of Jeil Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Ten Ren Tea Co Ltd TW:1233	Taiwan	NT$843.20 Million
Atrium Real Estate Investment Trust KLSE:5130	Malaysia	RM348.90 Million
Island Pharmaceuticals Ltd AU:ILA	Australia	AU$336.43K
Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd KQ:333430	Korea	₩38.62 Billion
Verrica Pharmaceuticals Inc NASDAQ:VRCA	USA	$31.71 Million
Keum Kang Steel Co. Ltd KQ:053260	Korea	₩21.31 Billion
Xlife Sciences AG SW:XLS	Switzerland	CHF144.76 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Jeil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Jeil Pharm (002620) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.22	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.46	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Jeil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Jeil Pharm (2011–2025)

The table below shows the annual total liabilities of Jeil Pharm from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩407.55 Billion ≈ $276.19 Million	-10.04%
2024-12-31	₩453.04 Billion ≈ $307.02 Million	-5.19%
2023-12-31	₩477.81 Billion ≈ $323.81 Million	+7.16%
2022-12-31	₩445.88 Billion ≈ $302.17 Million	+13.71%
2021-12-31	₩392.11 Billion ≈ $265.73 Million	+1.03%
2020-12-31	₩388.11 Billion ≈ $263.02 Million	+6.79%
2019-12-31	₩363.44 Billion ≈ $246.30 Million	+9.96%
2018-12-31	₩330.51 Billion ≈ $223.98 Million	+1117.39%
2017-12-31	₩27.15 Billion ≈ $18.40 Million	-88.68%
2016-12-31	₩239.91 Billion ≈ $162.58 Million	+17.73%
2015-12-31	₩203.78 Billion ≈ $138.10 Million	+36.43%
2012-12-31	₩149.36 Billion ≈ $101.22 Million	-2.21%
2011-12-31	₩152.74 Billion ≈ $103.51 Million	--

About Jeil Pharm

KO:002620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$79.90 Million

₩117.90 Billion KRW

Market Cap Rank

#20166 Global

#1075 in Korea

Share Price

₩7680.00

Change (1 day)

+0.00%

52-Week Range

₩6290.00 - ₩9280.00

All Time High

₩92178.44